Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes
In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension. Finally, Dr. Eagle shares some thoughts on a SMART-C collaborative meta-analysis of sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Dyslipidemia, Heart Failure and Cardiomyopathies, Pulmonary Hypertension and Venous Thromboembolism, Lipid Metabolism, Pulmonary Hypertension
Keywords: EaglesEyeView, Apolipoproteins B, Heart Disease Risk Factors, Pulmonary Arterial Hypertension, Treatment Outcome, Cardiometabolic Risk Factors, Sodium-Glucose Transporter 2 Inhibitors
